Sanofi Canada Statement in response to INESSS Decision Impacting Prostate Cancer Patients in Quebec

Sanofi Canada Statement in response to INESSS Decision Impacting Prostate 
Cancer Patients in Quebec 
MONTREAL, March 27, 2013 /CNW Telbec/ - "It is with great disappointment that 
Sanofi Canada has learned that the Institut national d'excellence en santé et 
en services sociaux (INESSS) has not approved the public listing of JEVTANA® 
(cabazitaxel)," said Jon Fairest, President and CEO of Sanofi Canada. "This 
decision means that those men living with prostate cancer in Quebec and 
dependent on the public system will not have access to public reimbursement 
for JEVTANA®." 
The provinces of Alberta, Saskatchewan, Manitoba and Ontario have already 
approved and recognized the value of JEVTANA® for patients living in these 
provinces. 
Sanofi Canada's ambition is to bring value, health and hope to Canadians 
through innovative healthcare solutions. Sanofi Canada stands behind the 
principle of access to the right medicine for the right patient at the right 
time, in strict accordance with advice and oversight from the appropriate 
healthcare practitioner. 
"It is an exciting time in the area of prostate cancer research with several 
new treatment options recently approved by Health Canada. Scientific 
research and clinical evidence suggests that there are subgroups of patients 
who respond differently to these different treatment options, therefore, the 
ability to individualize treatment is what is necessary to provide best 
outcomes for patients ," added Mr. Fairest. "Not having Cabazitaxel available 
to physicians and patients as a treatment option is extremely disappointing. 
We can just begin to imagine how frustrating this will be for patients and 
their families. New drugs with recognized therapeutic value need to be 
accessible to patients and clinicians in order to accomplish the objective and 
offer the best chance of extending survival." 
Regardless of therecent decision by INESSS to not approve JEVTANA®, Sanofi 
hopesto have the opportunity to work with INESSS in the very near future to 
help make this unique treatment option available to prostate cancer patients 
who can benefit from it. 
About JEVTANA® 
JEVTANA® is a second line treatment of castration resistant (hormone 
refractory) metastatic prostate cancer (mHRPC) in combination with prednisone 
in patients who have received prior treatment with a docetaxel containing 
regimen. 
Jevtana® is a registered trademark of Sanofi. 
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and 
distributes therapeutic solutions focused on patients' needs. Sanofi has core 
strengths in the field of healthcare with seven growth platforms: diabetes 
solutions, human vaccines, innovative drugs, consumer healthcare, emerging 
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY). 
Sanofi companies in Canada include sanofi-aventis Canada Inc. 
(pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (health 
and beauty), Genzyme (rare diseases) and Merial (animal health). Together they 
employ more than 1,700 people, mainly in the greater Montreal and Toronto 
areas. In 2011 Sanofi companies invested $151.7 million in R&D in Canada, 
creating jobs, business and opportunity throughout the country. For additional 
information, please visit http://www.sanofi.ca . 
MEDIA Caroline Martel Communications Consultant, Sanofi Canada 514-956-6120 
caroline.martel@sanofi.com 
SOURCE: Canadian Cancer Survivor Network (CCSN) 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/27/c8920.html 
CO: Canadian Cancer Survivor Network (CCSN)
ST: Quebec
NI: HEA HEA  
-0- Mar/27/2013 20:45 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.